Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.55 |
| ▸ | CTSV | O60911 | 2/20 | 0.55 |
| ▸ | CTSL | P07711 | 2/20 | 0.55 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.52 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.52 |
| ▸ | FLT3 | P36888 | 1/20 | 0.52 |
| ▸ | SRD5A1 | P18405 | 2/20 | 0.51 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.51 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.51 |
| ▸ | APP | P05067 | 1/20 | 0.51 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.51 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.50 |
| ▸ | MAOB | P27338 | 1/20 | 0.50 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.50 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29375765 | 1.00 | KDM4E (0.57) | KDM4EALDH1A1HPGDHDAC8CTSV | |
| SCHEMBL8202692 | 0.91 | KDM4E (0.64) | KDM4EALDH1A1HPGDCTSVCTSL | |
| SCHEMBL629641 | 0.90 | SLC16A3 (0.62) | KDM4EALDH1A1HPGDCTSVCTSL | |
| SCHEMBL8204838 | 0.90 | HDAC8 (0.53) | KDM4EHPGDHDAC8CTSVCTSL | |
| SCHEMBL29376294 | 0.88 | HDAC8 (0.52) | ALDH1A1HDAC8FLT3APPLRRK2 | |
| SCHEMBL2996551 | 0.88 | HDAC8 (0.52) | ALDH1A1HDAC8FLT3APPLRRK2 | |
| SCHEMBL1647498 | 0.87 | FOLH1 (0.63) | KDM4EALDH1A1HDAC8CTSVCTSL | |
| SCHEMBL7273836 | 0.87 | FOLH1 (0.61) | KDM4EALDH1A1HPGDCTSVCTSL | |
| SCHEMBL31550547 | 0.86 | HDAC8 (0.60) | KDM4EHDAC8CTSVCTSLFOLH1 | |
| SCHEMBL6404086 | 0.86 | HDAC8 (0.60) | KDM4EHDAC8CTSVCTSLFOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230019236-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | CALICO LIFE SCIENCES LLC (US) | 2023-01-19 | — | — | US | disclosed |
| CN-114025844-B | Protein tyrosine phosphatase inhibitors and methods of use thereof | 卡里科生命科学有限责任公司 | 2022-07-26 | — | — | CN | disclosed |
| CN-114025844-A | Protein tyrosine phosphatase inhibitors and methods of use thereof | 卡里科生命科学有限责任公司 | 2022-02-08 | — | — | CN | disclosed |
| EP-3938038-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | Calico Life Sciences LLC (US) | 2022-01-19 | — | — | EP | disclosed |
| WO-2021127499-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | CALICO LIFE SCIENCES LLC (US) | 2021-06-24 | — | — | WO | disclosed |
| CN-112955438-A | Protein tyrosine phosphatase inhibitors and methods of use thereof | 卡里科生命科学有限责任公司 | 2021-06-11 | — | — | CN | disclosed |
| EP-3810580-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | Calico Life Sciences LLC (US) | 2021-04-28 | — | — | EP | disclosed |
| US-10954202-B2 | Protein tyrosine phosphatase inhibitors and methods of use thereof | ABBVIE INC. (US) | 2021-03-23 | — | — | US | disclosed |
| US-20210009542-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | ABBVIE INC. | 2021-01-14 | — | — | US | disclosed |
| US-10851073-B2 | Protein tyrosine phosphatase inhibitors and methods of use thereof | ABBVIE INC. (US) | 2020-12-01 | — | — | US | disclosed |
| CN-105193797-A | Diabetes mellitus resistant oral medicine composition | ZHU ZHONGLIANG | 2015-12-30 | — | — | CN | disclosed |
| CN-105193796-A | Diabetes mellitus resistant oral medicine composition | ZHU ZHONGLIANG | 2015-12-30 | — | — | CN | disclosed |
| US-20100197744-A1 | Organic Compounds | BARNES DAVID | 2010-08-05 | — | — | US | disclosed |
| CN-101687828-A | Thiadiazole derivatives as antidiabetic agents | NOVARTIS AG | 2010-03-31 | — | — | CN | disclosed |
| EP-2155704-A1 | THIADIAZOLE DERIVATIVES AS ANTIDIABETIC AGENTS | Novartis Ag (CH) | 2010-02-24 | — | — | EP | disclosed |
| WO-2008148744-A1 | THIADIAZOLE DERIVATIVES AS ANTIDIABETIC AGENTS | NOVARTIS AG (CH) | 2008-12-11 | — | — | WO | disclosed |
| US-6136969-A | PROTEIN KINASE INHIBITORS; 4-HYDROXYBENZOIC ACID 3-(4-(4-FLUOROBENZOYLOXY)-BENZOYLAMINO)-AZEPAN-4-YL ESTER | HOFFMANN-LA ROCHE INC. (US) | 2000-10-24 | — | — | US | disclosed |
| US-5907038-A | PROTEIN KINASE INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 1999-05-25 | — | — | US | disclosed |
| EP-0836592-A1 | AZEPANES AND THEIR RING HOMOLOGUES FOR THERAPY AND PROPHYLAXIS OF PROTEIN KINASE MEDIATED DISEASES | F. HOFFMANN-LA ROCHE AG (CH) | 1998-04-22 | — | — | EP | disclosed |
| WO-1997002249-A1 | NOVEL AZEPANES AND THEIR RING HOMOLOGUES FOR THERAPY AND PROPHYLAXIS OF PROTEIN KINASE MEDIATED DISEASES | F. HOFFMANN-LA ROCHE AG (CH) | 1997-01-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197744-A1 | Organic Compounds | PTPRS, PTPRO, PTPRC | KDM4E 1788/4885ALDH1A1 3001/4885HPGD 2649/4885 |
| US-20230019236-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | PTPN1, PTPN2, PTPN18 | KDM4E 2069/4885ALDH1A1 3671/4885HPGD 2793/4885 |
| US-10851073-B2 | Protein tyrosine phosphatase inhibitors and methods of use thereof | PTPN1, PTPN2, PTPN18 | KDM4E 2069/4885ALDH1A1 3671/4885HPGD 2793/4885 |
| US-10954202-B2 | Protein tyrosine phosphatase inhibitors and methods of use thereof | PTPN1, PTPN2, PTPN18 | KDM4E 2069/4885ALDH1A1 3671/4885HPGD 2793/4885 |
| US-20210009542-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | PTPN1, PTPN2, PTPN18 | KDM4E 2069/4885ALDH1A1 3671/4885HPGD 2793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.